Monday, December 23, 2024
HomeTagsCheckMate -274 trial

CheckMate -274 trial

Adjuvant Opdivo (nivolumab) Continues to Provide Significant, Durable Clinical Benefits for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma After Three Years in CheckMate...

Bristol Myers Squibb announced three-year follow-up results from the Phase 3 CheckMate -274 trial, demonstrating significant sustained clinical benefits with Opdivo (nivolumab) for the adjuvant...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics